Rajiv Silva - Endo International CEO and President and Director
CEO
Mr. Rajiv De Silva is President Chief Executive Officer and a Director of Endo International Public Limited Company. Prior to joining Endo in March 2013 Mr. De Silva joined Endo Health Solutions as Chief Executive Officer and a Director in March 2013 and had served as the President of Valeant Pharmaceuticals International Inc. from October 2010 to January 2013 and served as its Chief Operating Officer Specialty Pharmaceuticals from January 2009 until January 2013. At Valeant he was responsible for all specialty pharmaceutical operations including sales and marketing research and development manufacturing and business development. Prior to joining Valeant Mr. De Silva held various leadership positions with Novartis. He served as President of Novartis Vaccines USA and Head Vaccines of the Americas at Novartis. During this time he played a key leadership role at Novartis Vaccines Diagnostics Division. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel Switzerland. Prior to his time at Novartis Mr. De Silva was a Principal at McKinsey Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. He has broad international experience having managed businesses in the United States Europe Canada Latin America Asia South Africa and AustraliaNew Zealand. Mr. De Silva was a Director of AMAG Pharmaceuticals Inc. and is currently a Member of the Board of Trustees at Kent Place School in Summit NJ.
| Age | 48 |
| Phone | 353 1 268 2000 |
| Web | https://www.endo.com |
Endo International Management Efficiency
The company has return on total asset (ROA) of 5.11 % which means that it generated a profit of $5.11 on every $100 spent on assets. This is normal as compared to the sector avarege. Endo International's management efficiency ratios could be used to measure how well Endo International manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 8.13 B in liabilities with Debt to Equity (D/E) ratio of 1.98, which is about average as compared to similar companies. Endo International PLC has a current ratio of 1.77, which is within standard range for the sector. Debt can assist Endo International until it has trouble settling it off, either with new capital or with free cash flow. So, Endo International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Endo International PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Endo to invest in growth at high rates of return. When we think about Endo International's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 4 records | CEO Age | ||
| Anne Noonan | Summit Materials | 61 | |
| Wayne Prejean | Drilling Tools International | 62 | |
| Thomas Hill | Summit Materials | 63 | |
| Marcel Hilmer | Forsys Metals Corp | N/A | |
Management Performance
| Return On Equity | 0.007 | |||
| Return On Asset | 5.11 |
Endo International PLC Leadership Team
Elected by the shareholders, the Endo International's board of directors comprises two types of representatives: Endo International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endo. The board's role is to monitor Endo International's management team and ensure that shareholders' interests are well served. Endo International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endo International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carrie Nichol, Chief Accounting Officer, Vice President Controller | ||
| William Spengler, Director | ||
| Arthur Higgins, Independent Director | ||
| Brian Lortie, President U.S. Branded Pharmaceuticals | ||
| Donald DeGolyer, Special Advisor to the CEO | ||
| William Montague, Director | ||
| Michael Hyatt, Director | ||
| Douglas Ingram, Director | ||
| Antonio Pera, President - Par Pharmaceutical | ||
| Domenic Ciarico, Executive Vice President Chief Commercial Officer - Sterile and Generics | ||
| Roger Kimmel, Chairman of the Board | ||
| Susan Hall, Chief Scientific Officer, Global Head of RandD and Quality and Executive VP | ||
| Sharad Mansukani, Director | ||
| Suketu Upadhyay, CFO and Executive VP | ||
| Nancy Hutson, Independent Director | ||
| Todd Sisitsky, Director | ||
| Patrick Barry, Executive Vice President and Chief Commercial Officer | ||
| Shane Cooke, Independent Director | ||
| Craig Paterson, Chief Medical Officer | ||
| Daniel Rudio, Senior Vice President Chief Accounting Officer, Controller | ||
| Camille Farhat, President of American Medical Systems, Inc | ||
| Paul Campanelli, President CEO, Director | ||
| Jill Smith, Director | ||
| Rajiv Silva, CEO and President and Director | ||
| Nina Goworek, Senior Director, Investor Relations | ||
| Blaise Coleman, Senior Vice President of Global Finance Operations and Interim CFO | ||
| Terrance Coughlin, COO, Executive Vice President | ||
| Matthew Maletta, Executive Vice President Chief Legal Officer |
Endo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endo International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.007 | |||
| Return On Asset | 5.11 | |||
| Profit Margin | (24.82) % | |||
| Operating Margin | 24.70 % | |||
| Current Valuation | 6.84 B | |||
| Shares Outstanding | 233.67 M | |||
| Shares Owned By Insiders | 0.79 % | |||
| Shares Owned By Institutions | 83.64 % | |||
| Number Of Shares Shorted | 41.45 M | |||
| Price To Earning | 0.37 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Endo International in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Endo International's short interest history, or implied volatility extrapolated from Endo International options trading.
Pair Trading with Endo International
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endo International position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endo International will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Eli Lilly could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eli Lilly when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eli Lilly - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eli Lilly and to buy it.
The correlation of Eli Lilly is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eli Lilly moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eli Lilly moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eli Lilly can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Endo International PLC information on this page should be used as a complementary analysis to other Endo International's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Endo Stock
If you are still planning to invest in Endo International PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Endo International's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |